Fig 1.
Schematic representation of Studies 1 and 2.
Fig 2.
Number of repetitions completed during the five leg extension sets in Study 1.
(ALK) alkalosis, (PLA) placebo, data are mean ± SEM.
Fig 3.
Percentage change (%) determined from measurements taken at rest (BASE) and immediately after the leg extension session in Study 1.
Voluntary rate of torque development (vRTD), rate of torque development normalised to the corresponding maximal voluntary contraction (nRTD), and rates of EMG rise for vastus lateralis (VLRER) and vastus medialis (VMRER) normalised to the superimposed M-wave (%); Figure includes the maximal rate and the time periods (0–25, 0–50 and 0–100 ms) associated with these measurements; (ALK) alkalosis, (PLA) placebo (PLA), data are mean ± SEM.
Table 1.
Presented are voluntary activation (VA; %), the maximal amplitude of the peak resting twitch amplitude at (PT; Nm), time-to-peak twitch (TPT; ms) and half relaxation time (1/2RT; ms), respectively, from pre- to post leg extension training session for placebo (PLA) and alkalosis (ALK) conditions.
Data are presented as mean ± SD.
Fig 4.
Pre-training blood pH and bicarbonate (HCO3-) values for each of the four training sessions throughout the 10-wk training program.
Two alkalosis (ALK) and two placebo (PLA)) within the weekly training cycle (e.g. Wk 1, Wk 2, etc.), data are mean ± SEM.
Fig 5.
Leg extension one-repetition maximum (1-RM) at the beginning (W0), mid-point (W5) and end (W10) of the 10-wk training program.
(ALK) alkalosis, (PLA) placebo, data are mean ± SEM.
Table 2.
Presented are voluntary rate of torque development (vRTD; Nm·s-1) and normalised rate of torque development (nRTD) to maximal voluntary torque at the beginning (W0), mid-point (W5) and end (W10) of the 10-wk training program for placebo (PLA) and alkalosis (ALK) conditions.
Data are presented as mean ± SD.
Table 3.
Presented are the rate of sEMG rise time periods for vastus lateralis (VL) and vastus medialis (VM) (VLRER; VLRER) normalised to the superimposed M-wave (%) at the beginning (W0), mid-point (W5) and end (W10) of the 10-wk training program for placebo (PLA) and alkalosis (ALK) conditions.
Data are presented as mean ± SD.
Table 4.
Presented are the amplitude of the peak resting twitch amplitude (PT; Nm), the time-to-peak twitch (TPT; ms) and 2) the half relaxation time (1/2RT; ms) at the beginning (W0), mid-point (W5) and end (W10) of the 10-wk training program for placebo (PLA) and alkalosis (ALK) conditions.
Data are presented as mean ± SD.